Encyclopedia of Cancer

Living Edition
| Editors: Manfred Schwab

Radiological Response Criteria

  • James P. B. O’Connor
  • Gordon C. Jayson
  • Alan Jackson
Living reference work entry
DOI: https://doi.org/10.1007/978-3-642-27841-9_4919-2


Radiological response criteria attempt to provide objective measures of tumor response to therapy. They are widely used as surrogate endpoints in clinical trials of cytotoxic chemotherapy and novel therapeutic agents.


Historical Developments

The need for standardized and objective outcome criteria to measure response to anticancer treatment has been recognized for over 50 years. In 1960, the Eastern Cooperative Oncology Group proposed that objective measurement of tumor size should be used as an endpoint in the evaluation of cytotoxic chemotherapy, since killing tumor cells had been shown to reduce lesion dimensions.

These principles were first codified in the World Health Organization (WHO) document, published in 1979. In particular four categories of response to chemoradiotherapywere defined – complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD). While many early assessments of tumor size relied on clinical...


Tyrosine Kinase Inhibitor Imatinib Proangiogenic Growth Factor Recurrent Anaplastic Astrocytoma Measure Tumor Response Halt Tumor Growth 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.


  1. Benjamin RS, Choi H, Macapinlac HA et al (2007) We should resist using RECIST, at least in GIST. J Clin Oncol 25:1760–1764CrossRefPubMedGoogle Scholar
  2. Dempsey MF, Condon BR, Hadley DM (2005) Measurement of tumor “size” in recurrent malignant glioma: 1D, 2D, or 3D? Am J Neuroradiol 26:770–776PubMedGoogle Scholar
  3. Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247CrossRefPubMedGoogle Scholar
  4. Michaelis LC, Ratain MJ (2006) Measuring response in a post-RECIST world: from black and white to shades of grey. Nat Rev Cancer 6:409–414CrossRefPubMedGoogle Scholar
  5. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205–216CrossRefPubMedGoogle Scholar
  6. Zia MI, Siu MI, Pond GR et al (2005) Comparison of outcomes of phase II studies and subsequent randomized control studies using identical chemotherapeutic regimens. J Clin Oncol 23:6982–6991CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • James P. B. O’Connor
    • 1
  • Gordon C. Jayson
    • 2
  • Alan Jackson
    • 3
  1. 1.Institute of Cancer SciencesUniversity of ManchesterManchesterUK
  2. 2.Cancer Research UK Department of Medical OncologyChristie HospitalManchesterUK
  3. 3.Centre for Imaging SciencesUniversity of ManchesterManchesterUK